company background image
PYC

PYC Therapeutics ASX:PYC Stock Report

Last Price

AU$0.061

Market Cap

AU$197.2m

7D

-3.2%

1Y

-60.6%

Updated

09 Aug, 2022

Data

Company Financials
PYC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PYC Stock Overview

PYC Therapeutics Limited, a development-stage biotechnology company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia.

PYC Therapeutics Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PYC Therapeutics
Historical stock prices
Current Share PriceAU$0.061
52 Week HighAU$0.16
52 Week LowAU$0.058
Beta0.50
1 Month Change-15.28%
3 Month Change-25.61%
1 Year Change-60.65%
3 Year Change69.44%
5 Year Change35.56%
Change since IPO-76.54%

Recent News & Updates

Jul 31
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

PYCAU BiotechsAU Market
7D-3.2%0.1%0.7%
1Y-60.6%-1.3%-8.0%

Return vs Industry: PYC underperformed the Australian Biotechs industry which returned -1.3% over the past year.

Return vs Market: PYC underperformed the Australian Market which returned -8% over the past year.

Price Volatility

Is PYC's price volatile compared to industry and market?
PYC volatility
PYC Average Weekly Movement11.7%
Biotechs Industry Average Movement11.7%
Market Average Movement10.5%
10% most volatile stocks in AU Market17.6%
10% least volatile stocks in AU Market4.6%

Stable Share Price: PYC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: PYC's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aRohan Hockingshttps://pyctx.com

PYC Therapeutics Limited, a development-stage biotechnology company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company’s preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and VP-002, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for retinal and central nervous system diseases.

PYC Therapeutics Limited Fundamentals Summary

How do PYC Therapeutics's earnings and revenue compare to its market cap?
PYC fundamental statistics
Market CapAU$197.22m
Earnings (TTM)-AU$16.82m
Revenue (TTM)AU$9.07m

21.4x

P/S Ratio

-11.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PYC income statement (TTM)
RevenueAU$9.07m
Cost of RevenueAU$0
Gross ProfitAU$9.07m
Other ExpensesAU$25.88m
Earnings-AU$16.82m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0053
Gross Margin100.00%
Net Profit Margin-185.43%
Debt/Equity Ratio0%

How did PYC perform over the long term?

See historical performance and comparison